Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Towards random sequencing or precision medicine in castration-resistant prostate cancer?

Loriot Y, Fizazi K.

Eur Urol. 2014 Jan;65(1):37-8. doi: 10.1016/j.eururo.2013.09.019. No abstract available.

PMID:
24075577
2.

Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.

Pal SK, Sartor O.

Nat Rev Clin Oncol. 2014 Sep;11(9):504-6. doi: 10.1038/nrclinonc.2014.128.

PMID:
25073005
3.

Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.

Thomson D, Charnley N, Parikh O.

Eur J Cancer. 2014 Mar;50(5):1040-1. doi: 10.1016/j.ejca.2013.12.017. No abstract available.

PMID:
24462374
4.

How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.

Francini E, Roviello G.

Tumour Biol. 2014 Aug;35(8):7391-2. doi: 10.1007/s13277-014-2145-0. No abstract available.

PMID:
24874054
5.

Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.

Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, De Bono JS.

Eur J Cancer. 2014 Mar;50(5):1042-3. doi: 10.1016/j.ejca.2013.12.016. No abstract available.

PMID:
24433842
6.

[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].

Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.

Urologe A. 2014 May;53(5):710-4. doi: 10.1007/s00120-014-3491-7. Review. German.

PMID:
24806804
7.

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.

Eur Urol. 2014 Jan;65(1):30-6. doi: 10.1016/j.eururo.2013.06.042.

PMID:
23849416
8.

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.

Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518.

9.

Enzalutamide in castration-resistant prostate cancer.

Burki TK.

Lancet Oncol. 2014 Jul;15(8):e312. No abstract available.

PMID:
25121180
10.

Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.

Schmid SC, Geith A, Böker A, Tauber R, Seitz AK, Kuczyk M, von Klot C, Gschwend JE, Merseburger AS, Retz M.

Adv Ther. 2014 Feb;31(2):234-41. doi: 10.1007/s12325-014-0092-1.

PMID:
24442834
11.

[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].

Brodszky V, Péntek M, Baji P, Rencz F, Géczi L, Szûcs M, Berczi C, Gulácsi L.

Magy Onkol. 2014 Sep;58(3):189-97. Review. Hungarian.

12.

Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?

Albiges L, Loriot Y, Massard C, Fizazi K.

Eur Urol. 2015 Nov;68(5):802-4. doi: 10.1016/j.eururo.2015.04.019. No abstract available.

PMID:
25922192
13.

Is in vitro-acquired resistance to enzalutamide a useful model?

Buonerba C, Di Lorenzo G.

Future Oncol. 2014 Dec;10(16):2551-3. doi: 10.2217/fon.14.212. No abstract available.

PMID:
25531044
14.

Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.

Tombal B.

Eur Urol. 2015 Aug;68(2):236-7. doi: 10.1016/j.eururo.2014.05.030. No abstract available.

PMID:
24908474
15.

Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?

Hélissey C, Rouanne M, Arnaud FX, Le Moulec S.

Anticancer Drugs. 2015 Mar;26(3):367-70. doi: 10.1097/CAD.0000000000000188.

PMID:
25486600
16.

Geography: an increasingly important variable in prostate cancer clinical trials.

Sartor O, Pal SK, Hermanson T, Bennett CL.

BJU Int. 2015 Jan;115(1):2-3. doi: 10.1111/bju.12930. No abstract available.

17.

New prostate cancer drugs hold promise.

[No authors listed]

Cancer. 2013 Jan 15;119(2):247-8. doi: 10.1002/cncr.27943. No abstract available.

19.

[Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies].

Berlin A, Fernández MI.

Rev Med Chil. 2015 Feb;143(2):223-36. doi: 10.4067/S0034-98872015000200010. Review. Spanish.

20.

[Novel drugs provide better therapy for prostate cancer].

Kellokumpu-Lehtinen P, Tammela T.

Duodecim. 2013;129(9):923-30. Review. Finnish.

PMID:
23786104
Items per page

Supplemental Content

Support Center